BC
ALT icon

Bridgefront Capital’s Altimmune ALT Stock Holding History

Bridgefront Capital’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,518
Closed -$72.6K – 591
2025
Q1 		$72.6K Sell
14,518
-2,705
-16% -$17.1K 0.02% 589
2024
Q4 		$124K Buy
+17,223
New +$132K 0.04% 535

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bridgefront Capital's ALT Position: Q2 2025 in Review

Bridgefront Capital sold out of Altimmune (ALT) in Q2 2025, closing a stake of 14,518 shares — an estimated $72.6K sold.

Bridgefront Capital first reported a position in ALT in Q4 2024 and held it in 2 quarters. The position peaked at $124K in Q4 2024. 180 funds tracked by Wall St. Rank hold ALT as of Q2 2025.

  • Bridgefront Capital reported no remaining Altimmune position as of Q2 2025 after selling out during the quarter.
  • Bridgefront Capital sold 14,518 Altimmune shares in Q2 2025, an estimated $72.6K.
  • Bridgefront Capital first reported a position in Altimmune in Q4 2024 and held it in 2 quarters.
  • Bridgefront Capital's Altimmune position peaked at $124K in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Altimmune as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.